Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04058-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Shaobo Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Transplantation, Division of Life Science and Medicine, The First Affiliated Hospital of USTC, University of Science and Technolo…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Transplantation, Division of Life Science and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230000, Anhui, China.
- Department of Liver Transplantation, Division of Life Science and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230000, Anhui, China. bjoern.nashan@gmail.com.
- Department of Liver Transplantation, Division of Life Science and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230000, Anhui, China. zsg0517@ustc.edu.cn.
Zitieren
APA
Zhang, S., Zhu, Z., Liu, L., Nashan, B., & Zhang, S. (2025). Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04058-4
Vancouver
Zhang S, Zhu Z, Liu L, Nashan B, Zhang S. Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04058-4
BibTeX
@article{Zhang2025,
author = {Zhang, Shaobo and Zhu, Zebin and Liu, Lianxin and Nashan, Björn and Zhang, Shugeng},
title = {Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04058-4}
}
EUVIMED